Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations

Patient characteristics and clinical outcomes

DNMT3A^mut was identified in 16.2% of the 884 patients in our cohort (143) (Supplementary Table 1). The median age of patients with DNMT3A^mut was 53 years (range: 17–82 years), significantly higher…